Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Partial agonism at nicotinic receptors with varenicline - a new approach to smoking cessation

Doggrell, SA (2006). Partial agonism at nicotinic receptors with varenicline - a new approach to smoking cessation. Expert Opinion on Pharmacotherapy,7(18):2599-2603.

Document type: Journal Article
Citation counts: Scopus Citation Count Cited 1 times in Scopus Article | Citations

Google Scholar Search Google Scholar

Title Partial agonism at nicotinic receptors with varenicline - a new approach to smoking cessation
Author Doggrell, SA
Journal Name Expert Opinion on Pharmacotherapy
Publication Date 2006
Volume Number 7
Issue Number 18
ISSN 1465-6566   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-33845598721
Start Page 2599
End Page 2603
Total Pages 5
Publisher Informa Healthcare
HERDC Category C1 - Journal Article (DEST)
Abstract Cigarette smoking is the leading preventable cause of death. Varenicline is a partial agonist at nicotinic alpha(4)beta(2) receptors being tested for smoking cessation. During a trial in which the drugs were administered for 12 weeks, the continuous abstinence rate was 17.7% in the placebo group, which improved to 29.5% with bupropion SIR and to 44.0% with varenicline 1 mg b.i.d. Abstinence rates for weeks 9 through 52 were 8.4, 16.1 and 21.9% for placebo, bupropion and varenicline, respectively. Prolonging the treatment with varenicline may give better quit rates. In this trial, after 12 weeks of open-label varenicline, the abstainers received either another 12 weeks of varenicline or placebo. At week 24, more of the participants in the varenicline group (70.5%) were abstinent than in the placebo group (49.6%). The most common adverse effect in both these trials with varenicline was nausea. This prompted a trial comparing the efficacy and safety of four varenicline dosing regimens, to determine whether a lower dose was effective and with reduced adverse effects. After 52 weeks, the abstinence rates were 3.9% in the placebo group, and higher in the varenicline 0.5 mg b.i.d. (18.5%) and 1 mg b.i.d. groups (22.4%). The rates of nausea were not significantly increased by varenicline 0.5 mg b.i.d., but were by varenicline 1 mg b.i.d. in summary, varenicline may give slightly higher smoking cessation rates than bupropion, but the smoking cessation rates, especially at 52 weeks, remain low.
Keywords bupropion
cigarette smoking
clinical trial
smoking cessation
varenicline
SUSTAINED-RELEASE BUPROPION
RANDOMIZED CONTROLLED-TRIAL
TREATMENT SERVICES
PLACEBO
EFFICACY
OUTCOMES
1-YEAR
DOI http://dx.doi.org/10.1517/14656566.7.18.2599   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 65 Abstract Views  -  Detailed Statistics
Created: Mon, 08 Sep 2008, 16:16:22 CST